| 1 | Proteasome inhibition in multiple myeloma: lessons for other cancers. 2020;318:C451 doi: 10.1152/ajpcell.00286.2019 |
| 2 | Targeting Reactive Oxygen Species Metabolism to Induce Myeloma Cell Death. 2021;13:2411 doi: 10.3390/cancers13102411 |
| 3 | Metabolic Reprogramming Induces Immune Cell Dysfunction in the Tumor Microenvironment of Multiple Myeloma. 2021;10: doi: 10.3389/fonc.2020.591342 |
| 4 | One Omics Approach Does Not Rule Them All: The Metabolome and the Epigenome Join Forces in Haematological Malignancies. 2021;5:22 doi: 10.3390/epigenomes5040022 |
| 5 | The Landscape of lncRNAs in Multiple Myeloma: Implications in the “Hallmarks of Cancer”, Clinical Perspectives and Therapeutic Opportunities. 2022;14:1963 doi: 10.3390/cancers14081963 |
| 6 | Myc-Related Mitochondrial Activity as a Novel Target for Multiple Myeloma. 2021;13:1662 doi: 10.3390/cancers13071662 |
| 7 | Myeloma Cells Deplete Bone Marrow Glutamine and Inhibit Osteoblast Differentiation Limiting Asparagine Availability. 2020;12:3267 doi: 10.3390/cancers12113267 |
| 8 | Mitochondrial metabolic determinants of multiple myeloma growth, survival, and therapy efficacy. 2022;12: doi: 10.3389/fonc.2022.1000106 |
| 9 | Choline PET/CT in Multiple Myeloma. 2020;12:1394 doi: 10.3390/cancers12061394 |
| 10 | Cytotoxic Effects of the Schweinfurthin Analog 5′-Methylschweinfurthin G in Malignant Plasma Cells. 2022;107:510 doi: 10.1159/000525299 |
Journal of Cancer Metastasis and Treatment
